22:47 , Apr 12, 2019 |  BioCentury  |  Finance

AskBio answers investors' call

Since 2001, gene therapy company Asklepios has subsisted chiefly on cash from licensing deals or transaction fees on programs sold off to biopharmas. Now, with $225 million in new series A funding from TPG Capital...
14:00 , Apr 11, 2019 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders...
17:46 , Mar 20, 2019 |  BC Extra  |  Company News

Pfizer gains option to buy liver gene therapy company Vivet

Pfizer's latest gene therapy deal gives it a 15% stake in Vivet and comes with an exclusive option to buy the rare liver disease company after the French company advances its Wilson disease candidate through...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
22:46 , Sep 20, 2017 |  BC Extra  |  Company News

Synpromics, Solid targeting DMD with transcription promoters

Synpromics Ltd. (Edinburgh, U.K.) will provide Solid Biosciences LLC (Cambridge, Mass.) access to muscle-selective synthetic DNA transcription promoter candidates based on Synpromics' PromPT platform which will be used to develop therapies for Duchenne muscular dystrophy....
22:33 , Jun 21, 2017 |  BC Extra  |  Company News

Sarepta gets option for Genethon's DMD gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it gained an option to obtain exclusive U.S. rights from non-profit organization Genethon (Evry, France) to a gene therapy to treat Duchenne muscular dystrophy. The collaboration covers a Genethon preclinical...
22:55 , May 19, 2017 |  BioCentury  |  Strategy

Full set in hemophilia

Pfizer Inc. ’s deal with Sangamo Therapeutics Inc. brings in what the pharma believes is the last of three mechanisms it needs to cover the hemophilia population with new non-factor replacement therapies. The companies announced...
21:15 , May 2, 2017 |  BC Extra  |  Company News

Management tracks

The Association of the British Pharmaceutical Industry named Lisa Anson president. She is president of the U.K. and Ireland division at AstraZeneca plc (LSE:AZN; NYSE:AZN). Effective June 30, President and CEO C. Randal Mills is...